1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pharmacologically induced polyploidy triggers BCL2 dependence in lymphomas
    Meeting Abstract

    Portelinha, A.; da Silva Ferreira, M.; Erazo, T.; Asgari, Z.; de Stanchina, E.; Younes, A.; Wendel, H. G.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: Initial experience in two clinical trials
    Meeting Abstract

    Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a phase I/II study
    Meeting Abstract

    Budde, E. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Primary efficacy and safety analysis of a global phase II study of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): The TIDAL study
    Meeting Abstract

    Phillips, T.; Jurczak, W.; Ribrag, V.; Linton, K.; Collin, G. P.; Lopéz-Jimenéz, J.; Reddy, N.; Mengarelli, A.; Musuraca, G.; Sheehy, O.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A SEER-Medicare analysis of the cost of disease progression after frontline R-CHOP in diffuse large B-cell lymphoma
    Meeting Abstract

    Burke, J. M.; Wang, R.; Hossain, F.; Li, J.; Masaquel, A.; Qiheng, S.; Matasar, M.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Cost-effectiveness of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
    Meeting Abstract

    Matasar, M.; Masaquel, A.; Rodrigo, H.; Launonen, A.; Ng, C.; Wang, R.; Fox, D.; Hossain, F.; Li, J.; Roth, J. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • First-line brentuximab vedotin plus chemotherapy improves overall survival in patients with stage III/IV classical Hodgkin Lymphoma: An updated analysis of ECHELON-1
    Meeting Abstract

    Straus, D.; Radford, J.; Connors, J.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J.; Advani, R.; Hutchings, M.; Evens, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
    Meeting Abstract

    Flowers, C.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Closing the gap: Implementation of a novel interactive virtual tumor board to improve expert knowledge sharing in malignant hematology
    Meeting Abstract

    Ciuro, J.; Henry, E.; Housri, N.; Banerjee, R.; Brem, E. A.; Brooks, T.; Derman, B. A.; Hill, B. T.; Hofmeister, C. C.; Lunning, M. A.; more...
    Blood (2022)

    Fulltext@MSK | Save